Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab IV for Primary Sclerosing Cholangitis with Underlying Inflammatory Bowel Disease
2014-003942-28Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) and inflammatory bowel disease (IBD) comparing Vedolizumab IV with Placebo IV (2 arms). Primary endpoint: No worsening in Ishak fibrosis staging score. Started Feb 2016; status: completed.
02
Drugs
vedolizumab
03
Conditions
Primary Sclerosing Cholangitis (PSC)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2014-003942-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003942-28.